28. (Amended) A method for inducing cell death comprising exposing a cell which overexpresses ErbB2 to an effective amount of [the] an isolated antibody [of claim 1] which binds to Domain 1 of ErbB2.

29. (Reiterated) The method of claim 28 wherein the cell is a cancer cell.

30. (Reiterated) The method of claim 28 wherein the cell is in a mammal.

31. (Reiterated) The method of claim 30 wherein the mammal is a human.

32. (Reiterated) The method of claim 28 further comprising exposing the cell to a second anti-ErbB2 antibody which does not bind to Domain 1 of ErbB2.

33. (Reiterated) The method of claim 28 further comprising exposing the cell to a second antibody which binds ErbB2 and inhibits growth of SKBR3 cells in cell culture by 50-100%.

34. (Reiterated) The method of claim 33 wherein the cell is exposed to the antibody which binds to Domain 1 of ErbB2 before the cell is exposed to the second antibody.

35. (Reiterated) The method of claim 33 wherein the second antibody binds to epitope 4D5 on ErbB2.

36. (Reiterated) The method of claim 35 wherein the second antibody has complementarity determining regions (CDRs) of antibody 4D5.

37. (Reiterated) The method of claim 28 further comprising exposing the cell to a growth inhibitory agent.

38. (Reiterated) The method of claim 28 further comprising exposing the cell to a

chemotherapeutic agent.

39. (Reiterated) The method of claim 28 further comprising exposing the cell to radiation.

40. (Amended) A method for inducing cell death comprising exposing a cell which overexpresses ErbB2 to an effective amount of [the antibody of claim 9] an isolated antibody which binds to ErbB2 and results in about 5 to 50 fold induction of annexin binding relative to untreated cell in an annexin binding assay using BT474 cells.

Please cancel non-elected claim 41 without prejudice to filing a continuing application directed thereto.

Please add the following claims to the application:

--42. (NEW) A method for inducing cell death comprising exposing a cell which overexpresses ErbB2 to an effective amount of a composition comprising an antibody which binds to Domain 1 of ErbB2 and a pharmaceutically acceptable carrier, wherein the antibody results in about 5 to 50 fold induction of annexin binding relative to untreated cell in an annexin binding assay using BT474 cells.

43. (NEW) The method of claim 42 wherein the cell is a cancer cell.

44. (NEW) The method of claim 42 wherein the cell is in a mammal.

45. (NEW) The method of claim 44 wherein the mammal is a human.

46. (NEW) The method of claim 28 wherein the antibody binds to epitope 7C2/7F3 on ErbB2.

47. (NEW) The method of claim 28 wherein the antibody induces death of a cell which

overexpresses ErbB2.

48. (NEW) The method of claim 47 wherein the antibody induces cell death via apoptosis.

49. (NEW) The method of claim 28 wherein the antibody is a monoclonal antibody.

50. (NEW) The method of claim 28 wherein the antibody has nonhuman complementarity determining region (CDR) residues and human framework region (FR) residues.

51. (NEW) The method of claim 28 wherein the antibody is humanized 7C2.

52. (NEW) The method of claim 28 wherein the antibody is a human antibody.

53. (NEW) The method of claim 28 wherein the antibody has complementarity determining regions (CDRs) of antibody 7C2 .

54. (NEW) The method of claim 28 wherein the antibody is an intact antibody.

55. (NEW) The method of claim 54 wherein the antibody comprises a human IgG heavy chain constant domain.--

---

REMARKS

Amendments

The ATCC address has been updated and the typographical error on page 49 has been corrected herein.

With respect to the claim amendments, the language from claims 1 and 9 has been included in claims 28 and 40, respectively. The further language in claim 40 finds specification support on at least page 14, lines 9-12 and page 32, lines 14-24.